Back to Results
First PageMeta Content
Endocrine system / Medicine / Eli Lilly and Company / Diabetes / Novo Nordisk / Insulin analog / Insulin aspart / Insulin degludec / Insulin / Peptide hormones / Recombinant proteins / Biology


Ryzodeg® (insulin degludec/insulin aspart) passed the review by the First Committee on Drugs of Pharmaceutical Affairs in Japan Bagsværd, Denmark, 3 December 2012 – Novo Nordisk today announced that Ryzodeg® (insuli
Add to Reading List

Document Date: 2012-12-03 01:33:41

Open Document

File Size: 118,48 KB

Share Result on Facebook

City

Japan Bagsværd / /

Company

New York Stock Exchange / Novo Nordisk A/S / /

Continent

Europe / /

Country

Switzerland / Japan / United States / Canada / Denmark / /

/

IndustryTerm

pharmaceuticals / diabetes care / healthcare / /

MedicalCondition

haemophilia / diabetes / /

MedicalTreatment

hormone therapy / hormone replacement therapy / /

Organization

FDA Advisory Committee / First Committee on Drugs of Pharmaceutical Affairs / First Committee on Drugs of Japan / Ministry of Health / /

Person

Frank Daniel Mersebach Lars Borup Jacobsen / Mike Rulis Ambre Morley / /

/

Product

NovoLog / /

PublishedMedium

the Japanese review / /

URL

www.novonordisk.com / /

SocialTag